SGLT2 inhibitors are an innovative treatment option in GSD-1b patients, as they treat the cause of neutropenia by eliminating the toxic metabolite – 1,5-AG6P – from neutrophils (3). Here, SLC5A2 is linked to glycogen storage disease Ib.